SEC’s TKT Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Securities & Exchange Commission staff has preliminarily decided to recommend taking action against Transkaryotic Therapies for securities law violations, the company said
You may also be interested in...
TKT’s Former CEO Settles SEC Fraud Charges For $1.2 Million
Charges date to 2005 for misleading statements made about Replagal; Transkaryotic Therapies was later acquired by Shire.
TKT’s Former CEO Settles SEC Fraud Charges For $1.2 Million
Charges date to 2005 for misleading statements made about Replagal; Transkaryotic Therapies was later acquired by Shire.
SEC Will Not Pursue Shire In Replagal Securities Fraud Case
SEC files civil action against former Transkaryotic Therapies CEO Richard Selden, but will not take action against TKT’s new parent company.